New stent technique aims to stop deadly bleeding without harming the brain

NCT ID NCT07253389

Recruiting now Disease control Sponsor: Air Force Military Medical University, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two ways of placing a stent in the liver to prevent repeat bleeding from swollen veins in the throat or stomach in people with cirrhosis. The standard method fully expands the stent, while the new method uses a smaller balloon to keep it slightly narrower. The goal is to see if the narrower stent works just as well to stop bleeding but causes fewer brain problems. About 648 adults in Chinese hospitals will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Underdilated TIPS procedure using a 6-mm balloon to expand a stent in the liver
What this could lead to: If successful, this could offer a safer way to prevent dangerous variceal rebleeding in cirrhosis patients, with fewer brain side effects.
What could go wrong: This is a mid-stage trial, and the underdilated stent might not prevent rebleeding as well as the standard approach. Results may not apply outside Chinese hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL VARICES BLEEDING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver esophageal varices with bleeding hepatic encephalopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROESOPHAGEAL VARICES BLEEDING LIVER CIRRHOSIS

Contacts and locations

Locations

Fourth Military Medical University
RECRUITING

Xi'an, Shaanxi, 710032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.